Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 2,948 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 2,948 shares of the company’s stock in a transaction on Saturday, April 18th. The stock was sold at an average price of $44.52, for a total value of $131,244.96. Following the completion of the sale, the director owned 2,964,774 shares of the company’s stock, valued at $131,991,738.48. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Price Performance

NASDAQ:SION opened at $41.79 on Wednesday. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -21.43 and a beta of 3.01. Sionna Therapeutics, Inc. has a one year low of $10.97 and a one year high of $46.46. The business has a fifty day moving average price of $37.94 and a 200-day moving average price of $38.63.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.15. On average, equities research analysts expect that Sionna Therapeutics, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

SION has been the subject of a number of analyst reports. UBS Group reiterated a “buy” rating on shares of Sionna Therapeutics in a research note on Monday, March 2nd. Citizens Jmp initiated coverage on Sionna Therapeutics in a research note on Tuesday, February 24th. They issued a “market outperform” rating and a $63.00 price target for the company. Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Guggenheim increased their price target on Sionna Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a research note on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.57.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SION. TD Asset Management Inc lifted its stake in Sionna Therapeutics by 74.3% in the third quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock worth $2,561,000 after purchasing an additional 37,116 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics in the third quarter worth about $147,000. Eventide Asset Management LLC bought a new stake in Sionna Therapeutics in the fourth quarter worth about $26,290,000. Seven Grand Managers LLC bought a new stake in Sionna Therapeutics in the fourth quarter worth about $2,057,000. Finally, ProShare Advisors LLC bought a new stake in Sionna Therapeutics in the fourth quarter worth about $202,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.